课题基金 / 基金详情

Role of Bcl-2 phosphorylation after microtubule disruption

Role of Bcl-2 phosphorylation after microtubule disruption
Bcl-2 磷酸化在微管破坏后的作用
批准号:
13680726
负责人:
SIMIZU Siro
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

SIMIZU Siro的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To clarify the role of Bcl-2 phosphorylation, we established the wild-type and several mutant-form of Bcl-2-expressing cell lines. We found that transmembrane region ?-deleted Bcl-2 (Bcl-2ΔTM), which was not localized at mitochondria, was constitutively phosphorylated in the cells. We identified Ser-87 residue within Bcl-2ΔTM protein as the phosphorylation site. To identify the responsible kinase for phosphorylation of Bcl-2ΔTM, we used several kinase inhibitors, and found that PD98059 and U0126, MEK1 inhibitors, suppressed phosphorylation of Bcl-2ΔTM. Moreover, in vitro kinase assay showed that ERK, a downstream kinase of MEK1, phosphorylated at Ser-87 residue of Bcl-2ΔTM. Both wild-type Bcl-2 and Bcl-2ΔTM could bind to ERK. Wild-type Bcl-2 could associate with PP2A, thus, wild-type Bcl-2 was not phosphorylated constitutively. On the other hand, Bcl-2ΔTM could interact with ERK, but not with PP2A. Moreover, Bcl-2 protein was constitutively phosphorylated in normal human blood cells, whereas Bcl-2 was not phosphorylated in human tumor cell lines.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
Kawatani, M., Uchi, M., Simizu, S., Osada, H., Imoto, M.: "Trnasmembrane domain of Bcl-2 is required for inhibition of ceramide synthesis, but not cytochrome c release in the pathway of inostamycin-induced apoptosis"Experimental Cell Research. (in press).
Kawatani, M.、Uchi, M.、Simizu, S.、Osada, H.、Imoto, M.:“Bcl-2 的 Trnasmembrane 结构域对于抑制神经酰胺合成是必需的,但在肌霉素途径中不需要抑制细胞色素 c 的释放
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
清水史郎, 長田裕之: "微小管作用薬の抗がん作用"分子細胞治療. 2. 366-369 (2001)
Shiro Shimizu、Hiroyuki Nagata:“微管作用药物的抗癌作用”《分子细胞疗法》2. 366-369 (2001)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
11
    Development of novel drug for bone-related diseases using Pirin inhibitors
    • 批准号:
      24310167
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.9万
    • 财政年份:
      2012
    • 负责人:
      SIMIZU Siro
    • 依托单位:
    国内基金
    基于“治风先治血 ,血行风自灭”从 ERKs/MAPK 信号通路研 究养血通痹汤对 RA 大鼠关节细胞的干预机制
    ERKs和p38在中华绒螯蟹精子获能和顶体反应中的调节作用
    • 批准号:
      31201974
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2012
    • 负责人:
      何琳
    • 依托单位:
    HBx通过激活ERKs影响细胞周期素D1蛋白质转移
    • 批准号:
      30771099
    • 项目类别:
      面上项目
    • 资助金额:
      30.0万元
    • 批准年份:
      2007
    • 负责人:
      鲁凤民
    • 依托单位: